Nueclear Web Banner
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

Quantitative determination of tumor platinum concentration of patients with advanced Breast, lung, prostate, or colorectal cancers undergone platinum-based chemotherapy


1 Department of Biomedical Physics and Engineering, School of Medicine; Advanced Health Technologies Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Biomedical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
4 Chemistry Department, Islamic Azad University of Firouzabad, Firouzabad, Iran

Correspondence Address:
Ali Reza Mehdizadeh,
Department of Biomedical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Advanced Health Technologies Research Center, Shiraz University of Medical Sciences, Shiraz
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Context: Previous studies have reported direct relationship between tumor reduction and its platinum concentration following platinum-based (Pt-based) chemotherapy. However, quantitative data of tumor platinum concentration have not yet been reported for the most common cancers. Aims: Determination of tumor platinum concentration of breast, lung, prostate, and colorectal cancers after Pt-based chemotherapy; and evaluation of the influence of chemo drug type, chemotherapy regimen, and time lapse from last chemotherapy on tumor platinum concentration. Materials and Methods: Tumor samples of patients with advanced breast, lung, prostate, and colorectal cancers undergone Pt-based chemotherapy were collected from pathology collection of various hospitals. The platinum concentration of each sample was measured by inductively coupled plasma optical emission spectrometry. The data were categorized by drug type, time lapse from last chemotherapy, and regimen type to evaluate their effects on platinum concentration. Statistical Analysis: ANOVA, Mann–Whitney U and Kruskal–Wallis tests were used. Results: Tumor platinum concentrations of breast, lung, prostate, and colorectal cancers were all obtained in the range of 1–10 μg/g tumor tissue. Large values of P (>0.05) indicate no significant differences between various chemo drug, regimen, and time groups. Conclusions: In general, the platinum concentration was higher in prostate and lower in lung tumors. The type of Pt-based chemo drug, time lapse from the last chemotherapy, and concurrency of other antineoplastic agents administered with Pt-based chemo drugs had no significant effect on tumor platinum concentration.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Mostaghimi H
    -  Mehdizadeh AR
    -  Jahanbakhsh M
    -  Dehghanian AR
    -  Askari R
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1931    
    PDF Downloaded98    

Recommend this journal